Dr. Khin Maung U (SPHS) retired from FDA. He shares medical reports with his former colleagues.
Here’s a short note posted by Dr. Khin Maung U.
While antimalarial drugs can cure the initial infection, the malaria parasites can get into the liver, hide in a dormant form, and cause recurrences months or years later. A second drug is used to prevent relapses. Current standard treatment to prevent relapses takes two weeks and many patients don’t finish taking every dose.
U.S. FDA approved on July 20, 2018, a simpler, one-dose new treatment, Krintafel (tafenoquine), to prevent relapses of malaria for patients 16 and older.
Krintafel (tafenoquine) only targets the kind of malaria that occurs mainly in South America and Southeast Asia.
One dose of Krintafel (tafenoquine) works about the same as the two-week standard treatment, preventing relapses in about three-quarters of patients over six months.